Phase III trial results bring subcutaneous Ocrevus closer to its potential approval

On 13 July 2023, Genentech announced positive results from its Phase III trial, OCARINA II (NCT05232825), investigating the efficacy of subcutaneous ocrelizumab, in patients diagnosed with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). In its intravenous (IV) formulation, ocrelizumab is known as Ocrevus and has been approved for use in multiple sclerosis (MS) since 2017.